Drug Profile

Research programme: kidney disorder therapeutics - Walden Biosciences

Alternative Names: Anti-suPAR antibody - Walden Biosciences

Latest Information Update: 11 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Walden Biosciences
Class Anti-inflammatories; Antibodies; Urologics
Mechanism of Action Urokinase plasminogen activator receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Kidney disorders

Most Recent Events

11 Nov 2025 Discontinued - Preclinical for Kidney disorders in USA (unspecified route) (Walden Biosciences pipeline; November 2025)
09 Mar 2023 Preclinical trials in Kidney disorders in USA (unspecified route) before March 2023
09 Mar 2023 Walden Biosciences announces intention to submit IND application for a phase-I trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com